Skip to content
Case report Open access

Transcatheter Mitral Valve-in-Valve Implantation Despite Left Atrial Appendage Thrombosis: A Challenging Therapeutic Strategy.

Nov 2026 · JACC Case Reports · pp. 111210 · 0 citations · 9 references
Medicine

Abstract

Background

Transcatheter mitral valve-in-valve (ViV) implantation is an alternative to redo surgery in high-risk patients with degenerated mitral bioprostheses. CASE SUMMARY An elderly woman presented with recurrent acute pulmonary edema due to severe stenosis of a degenerated mitral bioprosthesis. Redo surgery was considered prohibitive (EuroSCORE II: 15%). Transesophageal echocardiography revealed persistent left atrial appendage (LAA) thrombosis despite appropriate anticoagulation, increasing embolic risk. Given severe symptoms and lack of viable alternatives, transseptal mitral ViV implantation was successfully performed using the FLOWer cerebral embolic protection device, without neurological complications and with excellent hemodynamic results.

Discussion

LAA thrombosis is generally considered a relative contraindication to transseptal mitral interventions because of thromboembolic risk. This case highlights the potential role of cerebral embolic protection and individualized heart team decision-making in highly selected patients. TAKE-HOME MESSAGE Mitral ViV implantation with cerebral embolic protection may be feasible in selected patients with LAA thrombosis and prohibitive surgical risk.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.